Penicillin Allergy Testing and Delabelling
On this page
Direct answer
Nine of every ten patients carrying a penicillin-allergy label tolerate the drug on formal testing, and the label itself harms them — broader alternatives drive Clostridioides difficile infection, resistant organisms and treatment failure. IgE-mediated disease (urticaria, angio-oedema, anaphylaxis within one to two hours) is evaluated with penicilloyl-polylysine and minor-determinant skin testing followed by an oral amoxicillin challenge; low-risk remote rashes can go straight to supervised oral challenge. Cephalosporin cross-reactivity is about 1–2% overall and side-chain dependent — cefazolin and ceftriaxone are safe in most penicillin-allergic patients — a ladder of facts NEET-PG Medicine increasingly tests.
What you must remember
- About 90% of labelled patients are not allergic at evaluation; the label changes prescribing for decades.
- Immediate reactions (within 1–2 hours, up to 6): urticaria, angio-oedema, bronchospasm, anaphylaxis — IgE-mediated, testable.
- Delayed common reactions: benign maculopapular exanthems; delayed severe (SJS, TEN, DRESS, AGEP) — never rechallenge, never skin-test, avoid the class.
- Skin testing uses the major determinant penicilloyl-polylysine plus minor determinants (benzylpenicillin and its degradation products); negative predictive value with subsequent challenge exceeds 95–99% for IgE allergy.
- Low-risk patients (remote, childhood, non-immediate, mild rash) can proceed directly to a supervised single-dose oral amoxicillin challenge.
- Ampicillin rash in infectious mononucleosis is not allergy — a non-IgE-mediated phenomenon that does not contraindicate future penicillins.
- Cephalosporin cross-reactivity ~1–2% overall, governed by R1 side-chain similarity: avoid cefadroxil/cefaclor with amoxicillin allergy; cefazolin, ceftriaxone and cefepime carry dissimilar side chains.
- Carbapenem cross-reactivity is below 1% — effectively non-cross-reactive in IgE-mediated penicillin allergy.
- After successful challenge, update the case notes and allergy record — delabelling is only real when documented.
How to work through a typical case
A 34-year-old woman is admitted with pyelonephritis; her chart says "penicillin allergy — rash as a child, details unknown", and meropenem with its costs and covers is being requested.
Step one: take an allergy history with the four exam questions — what exactly happened, how soon after the dose, how long ago, and how it was managed. Her story: a diffuse rash two days into amoxicillin at age five, no mucosal involvement, no hospitalisation. Step two: classify the risk — a remote, delayed, mild exanthem in childhood is low risk for IgE-mediated disease; note the absence of blistering, mucosal lesions, fever or systemic features that would define SCAR and permanently contraindicate beta-lactams. Step three: delabel with a supervised oral challenge — one observed dose of amoxicillin with resuscitation facilities available; skin testing is added first when the history suggests immediacy or is vague about timing. Step four: if she tolerates the challenge, record "penicillin tolerated, allergy label removed" prominently, tell her in plain words, and prescribe accordingly. Step five: apply the cross-reactivity rules where testing is unavailable — if she had a true immediate amoxicillin allergy instead, ceftriaxone for her pyelonephritis remains reasonable given the dissimilar side chain, with the first dose observed; aztreonam and carbapenems stand as further options. Step six: never apply this pathway to a prior SCAR — those patients receive alternative classes and allergist-directed decisions only.
Where students slip
The commonest slip is treating the label as permanent fact: the exam expects "verify, then delabel" rather than automatic vancomycin or meropenem. Second, quoting 10% cephalosporin cross-reactivity — the modern answer is 1–2%, side-chain dependent. Third, skin-testing patients whose reaction was SJS or DRESS: testing applies to IgE immediacy only; SCAR is an absolute contraindication to re-exposure. Fourth, forgetting the mononucleosis ampicillin rash — a classic single-best-answer item where the correct response is "not a true allergy". Finally, performing the challenge without emergency preparedness, or forgetting to update the record afterward, wasting the entire exercise.
Frequently asked questions
What proportion of penicillin-allergy labels are false on formal testing?
About 90% of labelled patients tolerate penicillin when evaluated by skin testing and supervised oral challenge.
Which reagents constitute penicillin skin testing?
The major determinant penicilloyl-polylysine together with the minor determinant mixture (benzylpenicillin-derived), followed by oral amoxicillin challenge when negative, giving a negative predictive value above 95%.
Which reactions permanently contraindicate penicillin rechallenge?
Severe delayed cutaneous adverse reactions — Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS and acute generalised exanthematous pustulosis — plus any history of penicillin-induced anaphylaxis without successful evaluation.
How is cephalosporin cross-reactivity with penicillin currently framed?
Around 1–2% overall and determined by R1 side-chain similarity: agents like cefadroxil share the aminopenicillin side chain, while cefazolin, ceftriaxone and cefepime generally remain usable with observed first doses.
Is the ampicillin rash of infectious mononucleosis an allergy?
No — it is a non-IgE-mediated reaction of the illness itself; penicillins are not contraindicated for life after it resolves.